Results 51 to 60 of about 104,178 (284)

The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]

, 2007
Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Brand, Stephan, Göke, Burkhard, Spoettl, Gerald, De Toni, Enrico N., Meyer, Heinrich H. D., Meinecke, Jennifer, Zitzmann, Kathrin, Auernhammer, Christoph J.   +7 more
core   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Neuroendocrine neoplasms of the small bowel and pancreas

, 2019
The traditionally promulgated perspectives of neuroendocrine neoplasms as rare, indolent tumours are blunt and have been outdated for the last two decades.
Frilling, Andrea, Baum, Richard P., Oberg, Kjell, Kidd, Mark,, Kidd, Mark, Frilling, Andrea,, Clift, Ashley Kieran, Toumpanakis, Christos,, Baum, Richard P, Bodei, Lisa, Baum, Richard P.,, Clift, Ashley K, Modlin, Irvin, Öberg, Kjell,, Toumpanakis, Christos, Clift, Ashley Kieran,, Modlin, Irvin M.,, Bodei, Lisa,, Modlin, Irvin M.   +18 more
core   +1 more source

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

Molecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim, Hwiyeong Lee, Jin Hong, Daechan Park   +3 more
wiley   +1 more source

Neuroendocrine tumors of stomach and pancreas: diagnostic potential of radiomics, issues, and solutions

Digital Diagnostics
BACKGROUND: Radiomics is currently a promising and prospective tool for diagnosing and treating neuroendocrine neoplasms at various sites. This method is often used for differential diagnosis of gastrointestinal neuroendocrine tumors with other neoplasms
Nikolay V. Nudnov, Elina S-A. Shakhvalieva, David G. Karelidze, Aleksandr A. Borisov, Mikhail E. Ivannikov   +4 more
doaj   +1 more source

Update on Histological Reporting Changes in Neuroendocrine Neoplasms. [PDF]

, 2021
PURPOSE OF REVIEW Classification and nomenclature of neuroendocrine neoplasms (NEN) have frequently changed over the last years. These changes reflect both increasing knowledge and international standardisation.
Rodríguez-Calero, Antonio, Kim-Fuchs, Corina, Trepp, Roman, Marinoni, Ilaria, Kollár, Attila, Perren, Aurel, Bräutigam, Konstantin   +6 more
core   +1 more source

Applicability of mitotic figure counting by deep learning: a development and pan‐cancer validation study

FEBS Open Bio, EarlyView.
In this study, we developed a deep learning method for mitotic figure counting in H&E‐stained whole‐slide images and evaluated its prognostic impact in 13 external validation cohorts from seven different cancer types. Patients with more mitotic figures per mm2 had significantly worse patient outcome in all the studied cancer types except colorectal ...
Joakim Kalsnes, Maria X. Isaksen, Frida Julbø, Manohar Pradhan, Andreas Kleppe, Sepp De Raedt, Ole‐Johan Skrede, Turid Torheim, John Arne Nesheim, Hans Martin Mohn, Hanne A. Askautrud, Karolina Cyll, Wanja Kildal, Emma Rewcastle, Melinda Lillesand, Vebjørn Kvikstad, Emiel Janssen, Robert Jones, Odd Terje Brustugun, Bjørn Brennhovd, Erik Skaaheim Haug, Lill‐Tove Rasmussen Busund, Elin Richardsen, Sigve Andersen, Tom Dønnem, Kristina Lindemann, Gunnar Kristensen, Neil A. Shepherd, Marco Novelli, Knut Liestøl, David Kerr, Håvard E. Danielsen, Tarjei S. Hveem   +32 more
wiley   +1 more source

Primary Laryngeal Neuroendocrine Carcinoma – A Rare Entity with Deviant Clinical Presentation [PDF]

Journal of Clinical and Diagnostic Research, 2014
Primary laryngeal neuroendocrine carcinomas are rare neoplasms. WHO classifies them under five categories of which, the moderately differentiated neuroendocrine carcinoma is synonymous with atypical or malignant carcinoid tumour.
Hemalatha A. L, Anoosha K, Amita K, Vijay Shankar S, Avadhani Geeta K   +4 more
doaj   +1 more source

One size does not fit all: An in vitro evaluation of the effects of bezafibrate and medroxyprogesterone acetate on human SH‐SY5Y and U‐87 MG cancer cells

FEBS Open Bio, EarlyView.
Drugs previously repurposed to target blood cancers reduced neuroblastoma and glioblastoma cell growth and viability. However, their levels of anticancer activity were different and their clinical application may be problematic due to side effects at effective doses.
Abhishek Kharawatkar, Francesco Michelangeli, Farhat Latif Khanim, Christopher Martin Bunce, William Eustace Basil Johnson   +4 more
wiley   +1 more source

ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms.

, 2012
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine ...
O'Connor J, Baum R, Cadiot G, K. J. Klose, Grossman A, Sauvanet A, Scoazec JY, Bartsch D, Delle Fave G, Costa F, Pascher A, Brandi ML, Salazar R, Kianmanesh R, Plöckinger U, Klose KJ, Knigge U, Baudin E, Sundin A, Kelestimur F, FALCONI , MASSIMO, O. Nillson, M. Papotti, R. Salazar, Denecke T, Klöppel G, M. Caplin, Perren A, Eriksson B, F. Kelestimur, de Herder W, A. Sundin, Kwekkeboom D, Krenning E, Komminoth P, Ruszniewski P, Pavel M, Taal B, Vullierme MP, Nilsson O, Niederle B, Kos Kudla B, Arnold R, Rindi G, Tomassetti P, FALCONI, Massimo, Couvelard A, A. Pascher, Van Cutsem E, Öberg K, Jensen R, Sasano H, Caplin M, B. C. Conference Anlauf M, Wiedenmann B., U. Plöckinger, Gress T, Lopes JM, O'Toole D, Steinmüller T, Papotti M, Kaltsas G, Pape UF, Gross D, R. P. Baum   +64 more
core   +1 more source